Clinical Trials, Phase II as Topic

"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.

Descriptor ID	D017322
MeSH Number(s)	E05.318.760.250.500.210 N05.715.360.775.088.500.210 N06.850.520.450.250.250.210
Concept/Terms	Clinical Trials, Phase II as Topic Clinical Trials, Phase II as Topic Evaluation Studies, FDA Phase II as Topic Evaluation Studies, FDA Phase II as Topic Evaluation Studies, FDA Phase 2 as Topic Drug Evaluation, FDA Phase II as Topic Drug Evaluation, FDA Phase II as Topic Drug Evaluation, FDA Phase 2 as Topic

Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Epidemiologic Methods [E05.318]
Epidemiologic Study Characteristics as Topic [E05.318.760]
Clinical Studies as Topic [E05.318.760.250]
Clinical Trials as Topic [E05.318.760.250.500]
Clinical Trials, Phase II as Topic [E05.318.760.250.500.210]
Health Care [N]
Health Care Quality, Access, and Evaluation [N05]
Quality of Health Care [N05.715]
Health Care Evaluation Mechanisms [N05.715.360]
Epidemiologic Study Characteristics as Topic [N05.715.360.775]
Clinical Studies as Topic [N05.715.360.775.088]
Clinical Trials as Topic [N05.715.360.775.088.500]
Clinical Trials, Phase II as Topic [N05.715.360.775.088.500.210]
Environment and Public Health [N06]
Public Health [N06.850]
Epidemiologic Methods [N06.850.520]
Epidemiologic Study Characteristics as Topic [N06.850.520.450]
Clinical Studies as Topic [N06.850.520.450.250]
Clinical Trials as Topic [N06.850.520.450.250.250]
Clinical Trials, Phase II as Topic [N06.850.520.450.250.250.210]

Below are MeSH descriptors whose meaning is related to "Clinical Trials, Phase II as Topic".

Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in this website by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publications.

Bar chart showing 4 publications over 3 distinct years, with a maximum of 2 publications in 2020

To see the data from this visualization as text, click here.

Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.

Kishnani PS, Del Angel G, Zhou S, Rush ET. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2021 05; 133(1):113-121.

View in: PubMed
Warady BA, Ng E, Bloss L, Mo M, Schaefer F, Bacchetta J. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol. 2020 09; 35(9):1679-1697.

View in: PubMed
Chanu P, Schaefer F, Warady BA, Schmitt CP, Reigner B, Schnetzler G, Meyer Reigner S, Eisner M, Weichert A, Frey N. Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease. Br J Clin Pharmacol. 2020 04; 86(4):801-811.

View in: PubMed
Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, D?rk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC, Beesley J, Webb PM, Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, D?rst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010 Oct; 42(10):874-9.

View in: PubMed
Abdel-Rahman SM, Reed MD, Wells TG, Kearns GL. Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clin Pharmacol Ther. 2007 Apr; 81(4):483-94.

View in: PubMed

People

See all people

Similar Concepts

Top Journals